AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06514716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Geniculate Artery Embolization with Intra-articular Corticosteroid Injection (GAE with IACI)
Description: Participants will undergo geniculate artery embolization (GAE) followed by an intraoperative intra-articular corticosteroid injection (IACI). This combination aims to alleviate post-procedural pain and improve early functional outcomes in patients with knee osteoarthritis (OA).
Study NCT06514716 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Geniculate Artery Embolization alone (GAE alone)
Description: Participants will undergo geniculate artery embolization (GAE) without the additional intraoperative intra-articular corticosteroid injection. This procedure aims to serve as a control to evaluate the effectiveness and safety of GAE with IACI in comparison.
Study NCT06041308 — intervention group
Intervention type: OTHER
Intervention: valve
Description: bioprothetic valve versus mechanical valve
Study NCT04532645 — intervention group
Intervention type: DRUG
Intervention: Olaparib
Description: Olaparib
Study NCT04676958 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2
Description: Vitamin K2
Study NCT04676958 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Micro-crystalline cellulose
Description: Micro-crystalline cellulose
Study NCT05630521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Adherence Problem Solving for Hypertension
Description: The MASH program is a 12-week intervention containing two components: (1) four education modules on HTN causes, risks, treatment, and barriers to treatment; and (2) telehealth visits every 2 weeks with a registered nurse to deliver evidence-based managed problem solving strategies tailored on patients' responses to assessments of HTN beliefs, medication beliefs, and barriers impacting their medication adherence.
Study NCT06241690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the cold applications in post-suture pain reduces the child's pain
Description: The experimental groups was applied cold applications immediately after 20 minutes the suture. Later, The experimental groups was applied cold applications again for 20 minutes 1 hour, 2 hours and 6 hours after the suture.
Study NCT06306950 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near infrared spectroscopy neuromonitor to prevent cerebral desaturation
Description: patients were assigned into active treatment (intervention) or usual care (control) groups with cerebral oximetry monitoring using NIRS bilaterally (Root; Prime Medical Corporation, MASIMO, USA) \[17\]. After cleansing the adjacent skin area with alcohol, an adhesive optode pad was placed over each frontal to temporal area. Resting baseline rSO2 values were obtained after waiting at least 1 minute after the placement of the sensors.
Study NCT04878419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Educational Program
Description: Multiple virtual interactive sessions to provide education/knowledge about Type 1 Diabetes Mellitus care
Study NCT06646718 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Close kinetic chain exercise group
Description: ●Close kinetic chain exercise group: group A will receive forward step-ups, lateral step-ups, squats, sit-to-stand, and stoop-and-recover exercises. session will be initiated with a 10 min warm-up period, including stretching of the major muscles and muscle groups, then 40 min different exercises and terminated with a 10 min cool-down period in the form of aerobic exercises.
Study NCT06646718 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional physical therapy.
Description: ●Traditional physiotherapy: group B will receive stretching for the lower extremity muscles, namely hip flexors and adductors, hamstrings, and calf muscles; and strengthening exercises for core muscles, hip extensors, flexors and abductors, internal and external rotators of the hip, flexors and extensors of the knee, ankle dorsi flexors, kneeling exercises, and standing and gait training
Study NCT06646796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga with certified teacher, 3 times a week during 3 months.
Study NCT06645613 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation Device
Description: Transcranial magnetic stimulation uses FDA-approved coils to generate varying magnetic fields in the brain of the participant and induce an electric field in the underlying brain tissue. The standard intermittent Theta Burst Stimulation (iTBS) TMS protocol will be applied in this study. The same coil can be applied to generate sham stimulations that only generate sound and stimulations to the scalp without stimulating the brain.
Study NCT06645613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation Device
Description: Transcranial magnetic stimulation uses FDA-approved coils to generate varying magnetic fields in the brain of the participant and induce an electric field in the underlying brain tissue. The standard intermittent Theta Burst Stimulation (iTBS) TMS protocol will be applied in this study. The same coil can be applied to generate sham stimulations that only generate sound and stimulations to the scalp without stimulating the brain.
Study NCT04855110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin Sodium started on Day 2 after caesarean section (in a dose that achieves a therapeutic level as indicated by the cardiology consultant)
Description: Warfarin started on day 2 after caesarean section in patients with mechanical heart valve prosthesis
Study NCT04855110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin Sodium started on day 5 after caesarean section (in a dose that achieves a therapeutic level as indicated by the cardiology consultant)
Description: Warfarin started on day 5 after caesarean section in patients with mechanical heart valve prosthesis
Study NCT06108115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CueToSleep (Full Intervention Package)
Description: Individuals will be randomly allocated to receive the full Health Rhythms package (CueToSleep) program on their smartphones. The package includes 24/7 behavioral sensing from the participant's smartphone using the global positioning system, accelerometer, and screen on/off state, as well as a series of psychoeducational learning screens about the relationship among alcohol, mood disturbance and sleep, and personalized suggestions for behavior change to improve sleep that will be sent to the participant every 3 to 4 days. These suggestions will be based on behaviors indicated by the individual participant's sensor data over the previous 3 to 4 days.
Study NCT06421909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based educational intervention
Description: Mindfulness-based educational intervention is a structured program that incorporates principles of mindfulness to help individuals develop greater awareness and acceptance of their thoughts, feelings, and bodily sensations. The intervention typically includes mindfulness meditation practices, cognitive-behavioral techniques, and educational components about stress management and emotional regulation. By fostering a non-judgmental and present-focused attitude, participants learn to manage their symptoms more effectively and improve their overall quality of life.
Study NCT06115850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Music
Description: In the music intervention group, the patients received music intervention during RT for 10 consecutive days and listened to music for approximately 10-15 minutes in each session.
Study NCT04674774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan
Description: oral administration of tegoprazan-based bismuth quadruple therapy(tegoprazan 50 mg b.i.d, bismuth 300 mg q.i.d, metronidazole 500 mg t.i.d, tetracycline 500 mg q.i.d) for 14 days
Study NCT06444464 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: After baseline 24-hour blood pressure measurements are taken at visit 2, participants will attend a final study visit where they will engage in a single session of aerobic exercise. The exercise routines will include 5 to 10-minute warm-up and cool-down periods, along with a 30-minute workout. Twenty-four hour blood pressure measurements will be taken after the exercise bout.
Study NCT06444464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercise
Description: After baseline 24-hour blood pressure measurements are taken at visit 2, participants will attend a final study visit where they will engage in a single session of isometric exercise. The exercise routines will include 5 to 10-minute warm-up and cool-down periods, along with a 30-minute workout. Twenty-four hour blood pressure measurements will be taken after the exercise bout.
Study NCT05613608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in alcohol consumption, alcohol craving, peripheral markers of inflammation, and anxiety.
Study NCT04674774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: oral administration of PPI-based bismuth quadruple therapy(lansoprazole 30 mg b.i.d, bismuth 300 mg q.i.d, metronidazole 500 mg t.i.d, tetracycline 500 mg q.i.d) for 14 day
Study NCT05728593 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: parent-based occupational therapy
Description: Parent-based occupational therapy intervention While the therapist, parent and child were in the therapy area in the first session, the child received the same standard occupational intervention as the control group, and during this process, the parents recorded the therapy with a video recorder. In the second 20 minutes, three activities (such as eating, dressing or mobility activities), which had been decided and planned by the parent and the therapist before the session, were performed by the child and helped by the parent and video-recorded by the occupational therapist.
Study NCT05728593 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard occupational therapy intervention
Description: The sessions in this intervention included the creation of a client-based programme to increase each child's individual skills, functions and social participation. Each session lasted 45 minutes and took place twice a week until 10 sessions had been completed.~Various materials such as toys, blocks, paper and pencils were used to increase the child's participation in daily living, leisure and play activities.
Study NCT05613608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm.
Study NCT06137638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENA-001
Description: ENA-001 will be prepared in Ringer's lactate solution. A loading dose will be administered for 20 minutes followed by continuous infusion until the patient meets the criteria for PACU discharge (≥ 9 Aldrete score) or ABG reveals PaCO2 \< 30 mmHg with pH in the normal range. ENA-001 is for IV injection ready for use per subject by the investigational pharmacy, according to the randomization schedule.
Study NCT06295614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARC-IM System implantation
Description: Implantation of a stimulation lead on the lumbar level of the spinal cord and implantation of a neurostimulator in the abdominal region.
Study NCT06137638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ENA-001
Description: ENA-001 will be prepared in Ringer's lactate solution. A loading dose will be administered for 20 minutes followed by continuous infusion until the patient meets the criteria for PACU discharge (≥ 9 Aldrete score) or ABG reveals PaCO2 \< 30 mmHg with pH in the normal range. ENA-001 is for IV injection ready for use per subject by the investigational pharmacy, according to the randomization schedule.
Study NCT05484583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab + carboplatin/cisplatin + etoposide
Description: Induction period (3 weeks as a cycle, 4 cycles of administration): Durvalumab + carboplatin/cisplatin + etoposide, intravenous drip
Study NCT05484583 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Consolidation radiotherapy
Description: Consolidation radiotherapy period: radiotherapy for primary chest lesions + oligometastatic lesions.
Study NCT05484583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Maintenance phase (administered every 4 weeks): Durvalumab intravenous infusion
Study NCT06208345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life-Style app
Description: The modules of the Life-Style app are introduced and unlocked sequentially during the first weeks of the intervention phase. Afterwards the modules are fully available. Duration and frequency of app-use is not limited. The parents are accompanied by a coach through the app, who gives regular structured feedback and individual inputs. The coach has access to all data collected in the app.
Study NCT06649240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins and/or Ezetimibe
Description: Statin ± Ezetimibe to achieve target LDL-cholesterol level
Study NCT06649240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statins and/or Ezetimibe
Description: Statin ± Ezetimibe to achieve target LDL-cholesterol level
Study NCT05046535 — intervention group
Intervention type: BEHAVIORAL
Intervention: Sleep quality and physical activity
Description: Self-reported assessments will be used to measure the following: overall sleep quality, insomnia symptoms, Obstructive sleep apnea.~Physical activity will be measured objectively using the 6MWT, 9HPT, and cardiorespiratory fitness using the VO2 submaximal test on the recumbent stepper.
Study NCT05046535 — intervention group
Intervention type: GENETIC
Intervention: Nicotine dependence
Description: DNA sequencing for 20-25 subjects out of the whole sample will be performed. Sanger sequencing to all subjects will also be performed to identify related genes
Study NCT05046535 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nicotine and cotinine serum levels
Description: Cotinine serum level which is a major metabolite of nicotine and the preferred biomarker for measuring tobacco use will be measured together with nicotine levels using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).
Study NCT05046535 — intervention group
Intervention type: BEHAVIORAL
Intervention: Smoking
Description: Surveys that measure nicotine dependence and smoking behavior
Study NCT05444400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening
Description: Strengthening
Study NCT05444400 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional protocol
Description: Conventional protocol
Study NCT06649240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitor
Description: The use of PCSK9 inhibitors is permitted to achieve target LDL-cholesterol levels in participants who did not reach the target with statins ± ezetimibe.
Study NCT06649240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCSK9 inhibitor
Description: The use of PCSK9 inhibitors is permitted to achieve target LDL-cholesterol levels in participants who did not reach the target with statins ± ezetimibe.
Study NCT06648733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured pharmaceutical discharge management
Description: These patients will receive structured pharmaceutical discharge management from inpatient to outpatient care.
Study NCT06317142 — intervention group
Intervention type: DRUG
Intervention: Acipimox 250 mg Oral Capsule
Description: A subset of prediabetes individuals (first 10 IFG and 10 IGT subjects enrolled) will receive a 4-day Acipimox treatment (3x 250mg capsules for three days (one with breakfast,one with lunch and one with snack) and 1x 250mg in the morning of day 4.
Study NCT06178731 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: 3 min rTMS delivery with iTBS to the left DLPFC
Study NCT06178731 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: 3 min rTMS delivery with iTBS to the left DLPFC
Study NCT05230862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ladder Supplement
Description: Caffeine 200mg L-Theanine 200mg L-Citrulline 6g Creatine 5g Beta-Alanine 1.6g Phosphatidylserine 100mg
Study NCT06178731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: 2-15 min VR viewing, 15 min descriptive and imaginal recounting
Study NCT06178731 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Virtual Reality
Description: 2-15 min VR viewing, 15 min descriptive and imaginal recounting
Study NCT04917458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 4000 IU Oral Capsule, Liquid Filled
Description: -Vitamin D 25 (OH) or Cholecalciferol 4000 IU capsules, each capsules contain Vitamin D3 tablet @ 1000 IU Patients included into the study will be randomized into two groups and receive placebo (as control group) or cholecalciferol administered orally for 3 months.
Study NCT04917458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given to control group. It would be administrated orally, one capsule once a day for 30 days of study period
Study NCT04040452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Continuous ketorolac
Description: Patients randomized for the treatment arm of the study group will receive a continuous infusion of ketorolac plus an intermittent dose of placebo (plasmalyte) for 48 hours.
Study NCT04040452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous ketorolac
Description: Patients randomized for the treatment arm of the study group will receive a continuous infusion of ketorolac plus an intermittent dose of placebo (plasmalyte) for 48 hours.
Study NCT05723328 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Music Therapy Advocacy Recording Intervention (MTAR)
Description: Music Therapy Advocacy Recording Intervention (MTAR) is a sequence of group music therapy song-writing and recording sessions framed as a mental health awareness project to be shared with the general public.
Study NCT04892693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Oral Capsule
Description: - Patients will receive Talazoparib 1 mg orally once daily continuously, with or without food. Laboratory values will be monitored every 4 weeks until progression or unacceptable toxicity. Dose modifications should be made based on the observed toxicity
Study NCT04962724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled Xevinapant 200 mg (Oral Solution)
Description: \[14C\]-Xevinapant 200 mg administered as an oral solution on Day 1 of Part 1, containing approximately 100 microcurie (μCi) \[3.7 megabecquerel (MBq)\] in fasted conditions.
Study NCT04962724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled Xevinapant 100 μg (IV Solution)
Description: 100 μg \[14C\]-xevinapant single dose administered as an IV bolus on Day 1, containing approximately 0.2 μCi \[7.4 kilobecquerel (kBq)\].
Study NCT04962724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xevinapant 200 mg (Oral Solution)
Description: Xevinapant 200 mg administered as an oral solution on Day 1 of Part 2 in fasted conditions
Study NCT05803096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Self-Administered Nitrous Oxide
Description: Nitrous oxide administered at concentrations of mild sedation (20-45%) for the duration of prostate biopsy.
Study NCT05803096 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: Oxygen will be administered at 10 Liters/min for the duration of prostate biopsy.
Study NCT05149352 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU) for depression
Description: TAU for depression will be largely determined by the Dutch multidisciplinary practice guideline on depression (Spijker et al., 2013). This means that patients with CT-related depression will receive good clinical care, e.g. evidence-based psychotherapeutic interventions, such as cognitive behavioral therapy (CBT) or interpersonal therapy (IPT) combined with/or pharmacotherapy. Therapists who give TAU are not allowed to provide a trauma-focused intervention aimed at CT during the 12-week intervention period.
Study NCT05149352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU) for depression
Description: TAU for depression will be largely determined by the Dutch multidisciplinary practice guideline on depression (Spijker et al., 2013). This means that patients with CT-related depression will receive good clinical care, e.g. evidence-based psychotherapeutic interventions, such as cognitive behavioral therapy (CBT) or interpersonal therapy (IPT) combined with/or pharmacotherapy. Therapists who give TAU are not allowed to provide a trauma-focused intervention aimed at CT during the 12-week intervention period.